Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.87 and traded as low as $2.81. XBiotech shares last traded at $2.89, with a volume of 31,271 shares.
XBiotech Stock Performance
The stock has a market capitalization of $91.47 million, a PE ratio of -2.33 and a beta of 0.98. The stock has a 50 day moving average price of $2.88 and a 200-day moving average price of $3.17.
XBiotech (NASDAQ:XBIT - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) EPS for the quarter.
Hedge Funds Weigh In On XBiotech
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC raised its holdings in XBiotech by 13.9% during the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after acquiring an additional 3,661 shares during the period. Bank of America Corp DE lifted its position in shares of XBiotech by 42.0% in the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock valued at $79,000 after acquiring an additional 5,887 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after acquiring an additional 5,930 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of XBiotech by 7.5% in the fourth quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock valued at $360,000 after acquiring an additional 6,328 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of XBiotech by 15.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock valued at $218,000 after acquiring an additional 8,918 shares in the last quarter. 55.70% of the stock is currently owned by hedge funds and other institutional investors.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Further Reading
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access